KYMR - Kymera Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KYMR is currently covered by 16 analysts with an average price target of $60.67. This is a potential upside of $16.19 (36.4%) from yesterday's end of day stock price of $44.48.

Kymera Therapeutics's activity chart (see below) currently has 70 price targets and 95 ratings on display. The stock rating distribution of KYMR is 32.73% HOLD and 67.27% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 62.94% with an average time for these price targets to be met of 241.93 days.

Highest price target for KYMR is $70, Lowest price target is $44, average price target is $56.14.

Most recent stock forecast was given by VIKRAM PUROHIT from MORGAN STANLEY on 03-Jul-2025. First documented stock forecast 15-Sep-2020.

Currently out of the existing stock ratings of KYMR, 18 are a HOLD (32.73%), 37 are a BUY (67.27%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$70

$25.52 (57.37%)

$79

10 days ago
(03-Jul-2025)

11/17 (64.71%)

$25.21 (56.28%)

191

Buy

$53

$8.52 (19.15%)

$57

17 days ago
(26-Jun-2025)

6/9 (66.67%)

$7.29 (15.95%)

169

Buy

$60

$15.52 (34.89%)

$60

17 days ago
(26-Jun-2025)

5/9 (55.56%)

$14.29 (31.26%)

45

Hold

$60

$15.52 (34.89%)

$41

1 months 10 days ago
(03-Jun-2025)

6/8 (75%)

$16.42 (37.68%)

218

Buy

$64

$19.52 (43.88%)

$47

1 months 10 days ago
(03-Jun-2025)

3/4 (75%)

$20.42 (46.86%)

403

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KYMR (Kymera Therapeutics) average time for price targets to be met?

On average it took 241.93 days on average for the stock forecasts to be realized with a an average price target met ratio 62.94

Which analyst has the current highest performing score on KYMR (Kymera Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the most public recommendations on KYMR (Kymera Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on KYMR

Which analyst is the currently most bullish on KYMR (Kymera Therapeutics)?

Eliana Merle with highest potential upside - $25.52

Which analyst is the currently most reserved on KYMR (Kymera Therapeutics)?

Richard Law with lowest potential downside - -$7.48

Kymera Therapeutics in the News

Kymera Therapeutics stock price target lowered to $65 at Brookline Capital

Investing.com – Brookline Capital Markets has lowered its price target on Kymera Therapeutics (NASDAQ:KYMR) to $65.00 from $70.00 while maintaining a Buy rating on the stock. The new target represents a significant upside from the current trading price of $44.79, with InvestingPro data showing strong analyst consensus supporting a bullish outlook. The firm adjusted its...

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera Therapeutics, Inc. KYMR reported a first-quarter 2025 loss of 82 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, Kymera reported a loss of 69 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) The year-over-year deterioration was due...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?